Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
2023 · npj Breast Cancer · 14 citations
https://doi.org/10.1038/s41523-023-00544-z
A
Alyse Staley
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
21
Papers
67
Citations
5
h-index
2
i10-index
Alyse Staley is an academic researcher from University of Colorado Anschutz Medical Campus. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Advanced Breast Cancer Therapies & Estrogen and related hormone effects. The author has an h-index of 5, co-authored 18 publications.
ORCID: 0000-0001-8938-5063Papers by this author
worksThe Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
2024 · JTO Clinical and Research Reports · 8 citations
https://doi.org/10.1016/j.jtocrr.2024.100637
The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer
2024 · Advances in Radiation Oncology · 3 citations
https://doi.org/10.1016/j.adro.2024.101516
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors
2025 · JTO Clinical and Research Reports · 0 citations
https://doi.org/10.1016/j.jtocrr.2025.100870
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat